Keybanc has initiated coverage on LivaNova PLC (LIVN) with an Overweight rating, marking the firm's first assessment of the company. This decision reflects Keybanc's analysis of LivaNova's business, industry dynamics, and growth prospects.
LivaNova, based in Great Britain, is a global medical technology company that develops therapeutic solutions for patients, healthcare professionals, and healthcare systems. The firm operates in two segments: Cardiopulmonary and Neuromodulation. Its Cardiopulmonary segment focuses on products such as heart-lung machines and oxygenators, while the Neuromodulation segment specializes in devices for treating drug-resistant epilepsy and difficult-to-treat depression.
As of December 18, 2025, LivaNova's stock is priced at $63.27, with a market capitalization of $3.4 billion. The company has reported a trailing twelve-month (TTM) earnings per share (EPS) of -4.01. Upcoming earnings are scheduled for May 5, 2026, with an EPS estimate of $0.91 and revenue expectations of $346.2 million.
The analyst consensus as of December 1, 2025, includes 6 Strong Buy, 6 Buy, and 4 Hold ratings, indicating a general positive outlook among analysts. Recent earnings performance has shown positive surprises, with Q3 2025 EPS at $1.11, exceeding estimates by 18.4%. Such decisions reflect the evolving outlook for LivaNova as it continues to navigate the healthcare technology landscape.